PTIX (Protagenic Therapeutics) 5-Year EBITDA Growth Rate: -8.60% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
22 GF Score
Price $0.18
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics 5-Year EBITDA Growth Rate?

Protagenic Therapeutics PTIX +8.02% 22 5-Year EBITDA Growth Rate is -8.60% as of Dec. 2025. GuruFocus rates PTIX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Protagenic Therapeutics's EBITDA per Share for the three months ended in Dec. 2025 was $-0.47.

During the past 3 years, the average EBITDA Per Share Growth Rate was -0.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Protagenic Therapeutics was 26.50% per year. The lowest was -8.00% per year. And the median was -1.90% per year.

Protagenic Therapeutics  (OTCPK:PTIX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Protagenic Therapeutics 5-Year EBITDA Growth Rate Related Terms

PTIX vs CERO, CYTOF, CARM: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Protagenic Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protagenic Therapeutics 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's 5-Year EBITDA Growth Rate falls into.


PTIX
22GF Score
Protagenic Therapeutics Inc PTIX
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of -8.60% mean?
Protagenic Therapeutics (PTIX) has a 5-Year EBITDA Growth Rate of -8.60% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Protagenic Therapeutics and its competitors.
Is Protagenic Therapeutics' 5-Year EBITDA Growth Rate too high?
Protagenic Therapeutics' current 5-Year EBITDA Growth Rate is -8.60%. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' 5-Year EBITDA Growth Rate compare to CERO and CYTOF?
Protagenic Therapeutics' 5-Year EBITDA Growth Rate of -8.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current 5-Year EBITDA Growth Rate is -8.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current 5-Year EBITDA Growth Rate of -8.60%. The current 5-Year EBITDA Growth Rate is -8.60%. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current 5-Year EBITDA Growth Rate is -8.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score

Get the complete analysis for PTIX

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price